Animal models, particularly with humanized ACE2 transgenic mice, could determine if auranofin has the potential to reduce SARS-CoV-2-associated IL-6-derived pathogenicity and decrease COVID-19 immunopathology. The gene discussed is IL6; the disease is COVID-19.